Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2022-05-09 15:55
Comprehensively promoting rural revitalization is a major task in achieving the great rejuvenation of the Chinese nation. Health and beauty are deeply aware that rural revitalization requires health first. Health is related to the well-being of the people and is an important cornerstone of common prosperity. In the future, Health will continue to give full play to its own advantages, actively assume social responsibilities, and contribute to rural revitalization through health-related public welfare.
Time Posted：2022-04-29 17:34
On the evening of April 24, Jiankangyuan officially disclosed its 2022 first-quarter report. During the reporting period, the company achieved operating revenue of 4.657 billion yuan, a year-on-year increase of 12.36%; net profit attributable to shareholders of the listed company reached 461 million yuan, a year-on-year increase of 25.52%; net cash flow from operating activities reached 872 million yuan, a year-on-year increase of 76.27%, and its sustainable profitability continued to strengthen.
Time Posted：2022-04-22 16:03
Recently, Jiankangyuan (600380.SH) announced that it had received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for Levosalbutamol Hydrochloride Nebulization Solution (3ml:1.25mg), approving the addition of the 3ml:1.25mg specification. As of the announcement date, the cumulative R&D investment in Levosalbutamol Hydrochloride Nebulization Solution (Lishutong) was approximately RMB 39.5016 million. This product is based on Jiankangyuan's already approved Levosalbutamol Hydrochloride Nebulization Solution (specifications: 3ml:0.63mg, 3ml:0.31mg, approval numbers: H20193279, H20205016), with an application for the addition of the 3ml:1.25mg specification. The initial submission of the drug registration application was accepted on August 25, 2021 (acceptance number: CYHB2101735).
Time Posted：2022-04-18 16:40
It is understood that the next-generation Omicron strain vaccine of Lizhu Group has shown a good neutralizing effect against Omicron in mice. The neutralizing antibody titer of two doses of the Omicron strain vaccine against Omicron pseudovirus reached 1304, which is 52 times that of the V01 prototype vaccine and is comparable to the neutralizing antibody (1230) of two doses of V01 against the wild type.
Time Posted：2022-04-14 16:45
LIZHU Reagent's self-developed novel coronavirus (2019-nCoV) antigen detection kit (latex method) has advantages over the colloidal gold method in detection: Firstly, it uses colored latex microspheres as signal markers. The latex microspheres have a uniform size and are 5-10 times larger than conventional colloidal gold particles, thus improving the detection sensitivity of the latex method; Secondly, carboxyl and other activating groups are incorporated into the colored latex microspheres during synthesis, and the labeled antibody and latex are covalently linked through chemical bonds, which is more stable than the charge connection between colloidal gold and protein.
Time Posted：2022-04-13 11:05
Analysis of subgroup data from three Phase III clinical trials conducted in Pakistan and Malaysia showed that V-01 had a 71.83% protective efficacy in people with underlying diseases and a 61.19% protective efficacy in high-risk populations (60 years of age or older or with underlying diseases). The trial results further indicate that V-01 has a higher protective efficacy in high-risk populations.
Time Posted：2022-04-01 11:16
Understanding Health Yuan's 2021 Annual Report in One Chart: Non-net attributable net profit to shareholders of the parent company reached 1.225 billion yuan in 2021, a year-on-year increase of 26.72%.
Time Posted：2022-03-31 17:54
According to the report, the company achieved operating revenue of 15.904 billion yuan in 2021, a year-on-year increase of approximately 17.62%; net profit attributable to shareholders of the listed company reached 1.328 billion yuan, a year-on-year increase of approximately 18.57%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.225 billion yuan, a year-on-year increase of approximately 26.72%, with double-digit growth in both revenue and profit. In addition, the basic earnings per share of Health Yuan was 0.6864 yuan, a year-on-year increase of 19.31%. The board of directors has resolved to distribute a cash dividend of RMB 1.50 per 10 shares to all shareholders.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.